1
|
Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D, Lolis N, Georgatou N, Toubis M, Pappas C, Tsoukalas G. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010; 21:2227-2232. [PMID: 20439345 PMCID: PMC2962260 DOI: 10.1093/annonc/mdq234] [Citation(s) in RCA: 88] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: Liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues. The primary objectives were to determine nephrotoxicity, gastrointestinal side-effects, peripheral neuropathy and hematological toxicity and secondary objectives were to determine the response rate, time to tumor progression (TTP) and survival. Patients and methods: Two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m2 of liposomal cisplatin and 135 mg/m2 paclitaxel (arm A) or 75 mg/m2 cisplatin and 135 mg/m2 paclitaxel (arm B), once every 2 weeks on an outpatient basis. Two hundred and twenty-nine patients were assessable for toxicity, response rate and survival. Nine treatment cycles were planned. Results: Arm A patients showed statistically significant lower nephrotoxicity, grade 3 and 4 leucopenia, grade 2 and 3 neuropathy, nausea, vomiting and fatigue. There was no significant difference in median and overall survival and TTP between the two arms; median survival was 9 and 10 months in arms A and B, respectively, and TTP was 6.5 and 6 months in arms A and B, respectively. Conclusions: Liposomal cisplatin in combination with paclitaxel has been shown to be much less toxic than the original cisplatin combined with paclitaxel. Nephrotoxicity in particular was negligible after liposomal cisplatin administration. TTP and survival were similar in both treatment arms.
Collapse
Affiliation(s)
| | - D Antoniou
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - J Dimitroulis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - P Michalopoulou
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - A Bastas
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - K Marosis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | | | - A Provata
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - P Yiamboudakis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - D Veldekis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - N Lolis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - N Georgatou
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - M Toubis
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - Ch Pappas
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| | - G Tsoukalas
- Pneumonology Clinics, Hospital of Thoracic Disorders, Athens, Greece
| |
Collapse
|
2
|
Stathopoulos G, Dimitroulis J, Toubis M, Stathopoulos J, Koutantos J, Rigatos S, Athanasiadis A, Antoniou D, Giamboudakis P. 6599 POSTER Comparison of cisplatin–paclitaxel combination versus cisplatinetoposide as first line chemotherapy in SCLC. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71427-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
3
|
Dimitroulis J, Toubis M, Antoniou D, Marosis C, Armenaki U, Stathopoulos GP, Giamboudakis P, Veslemes M, Michalopoulou P, Christou F, Georgatou N, Grigoratou T, Karaindros D, Katis K. Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: a phase II study. Anticancer Res 2006; 26:1397-402. [PMID: 16619550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
BACKGROUND In the present study, 3 cytotoxic agents were combined as front-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. All 3 drugs have been used in other 2-agent combinations and have been shown to be effective as first-line therapy. PATIENTS AND METHODS Sixty-one (53 male, 8 female, median age 65 years old) out of 67 patients were evaluable for response and toxicity. Eighty percent of the patients were stage IIIB and IV and 20% were inoperable stage IIIA. In order to obviate toxicity as much as possible, paclitaxel 135 mg/m2 was combined with gemcitabine 1000 mg/m2 for the first cycle, and 2 weeks later with vinorelbine 25 mg/m2, for the second cycle; this alternate schedule was repeated every 2 weeks for 9 cycles. RESULTS No complete responses were observed; there was a 37.7% partial response rate and stable disease in 31.1% of the patients. The median survival was 13 months and 1-year survival, 53%. Myelotoxicity involved grade 3 neutropenia in 3.3% of the patients and grade 4 in 1.6%. CONCLUSION Adverse reactions were few in this alternate administration of paclitaxel-gemcitabine and paclitaxel-vinorelbine in NSCLC patients; in more than half of the patients there was long median and 1-year survival.
Collapse
Affiliation(s)
- J Dimitroulis
- Sixth Clinic, Sotiria Hospital of Chest Diseases, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Dimitroulis J, Toubis M, Antoniou D, Giamboudakis P, Marosis C, Armenaki U, Veslemes M, Michalopoulou P, Christou F, Georgatou N, Stathopoulos GP. Alternative administration of paclitaxel-gemcitabine and paclitaxel-vinorelbine as first line treatment in NSCLC patients. A phase II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - M. Toubis
- Hosp of Thoracic Diseases, Athens, Greece
| | | | | | - C. Marosis
- Hosp of Thoracic Diseases, Athens, Greece
| | | | | | | | | | | | | |
Collapse
|
5
|
Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004; 91:482-8. [PMID: 15238986 PMCID: PMC2409833 DOI: 10.1038/sj.bjc.6602010] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
To compare irinotecan (CPT-11)+gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing after docetaxel-cisplatinum-based therapy. A total of 147 evaluable, pretreated patients, with NSCLC, received either gemcitabine (1000 mg m(-2), days 1 and 8)+CPT-11 (300 mg m(-2), day 8) (Group A, n=76) or CPT-11 (300 mg m(-2), day 1) (Group B, n=71), every 3 weeks. All patients were evaluable for response and toxicity. The objective response rate was 18.4% (95% CI: 9.71-27.14%) and 4.2% (95% CI: 0-8.90%) (P=0.009) for groups A and B, respectively. No significant differences between the two groups in terms of the median duration of response, time to tumour progression, overall survival and 1-year survival were observed. The CPT-11/gemcitabine regimen significantly improved the patients' quality of life ('general mood today' (P=0.014), 'coughing' (P=0.003) and 'intensity of symptoms' (P=0.034)) compared with CPT-11. More cycles had to be delayed (P=0.001) and required prophylactic growth factor support (P=0.001) in Group A than B. Three (3.9%) patients in Group A and eight (11.3%) in Group B developed febrile neutropenia (P=0.09); one patient died of sepsis in each group. Three additional (Group A, n=1; Group B, n=2) treatment-related deaths were observed. Grade 3-4 haematologic toxicity was comparable in the two groups except anaemia (P=0.03 in favour of CPT-11). Other nonhaematologic toxicities were mild and similar in the two groups. CPT-11+gemcitabine resulted in a higher response rate and better control of disease-related symptoms than CPT-11 alone, but without any improvement in the overall survival.
Collapse
Affiliation(s)
- V Georgoulias
- Department of Medical Oncology, University General Hospital of Heraklion, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis C, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N, Georgoulias V. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001; 32:179-87. [PMID: 11325489 DOI: 10.1016/s0169-5002(00)00212-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Docetaxel in combination with gemcitabine is an active front-line chemotherapy regimen against non-small cell lung cancer (NSCLC) with acceptable toxicity. A multicenter phase II study was conducted in order to determine the toxicity and efficacy of this combination, as salvage treatment in patients progressing after a cisplatin-based front line regimens. PATIENTS AND METHODS Thirty-two patients with histologically confirmed, bidimensionally measurable NSCLC, who failed prior cisplatin-based chemotherapy were enrolled. The patients' median age was 62.5 years, 29 (91%) were male, 23 (72%) had disease stage IV, and 22 (69%) had a performance status (WHO) 0-1. Gemcitabine (900 mg/m(2)) was administered on days 1 and 8 and docetaxel (100 mg/m(2)) on day 8, after appropriate premedication. rhG-CSF (150 microg/m(2)) was given prophylactically from day 9 to 15. Treatment was repeated on an outpatient basis every three weeks. RESULTS A total of 127 chemotherapy cycles were administered. In an intention-to-treat analysis five patients (15.6%; 95% CI: 3.04-28.21%) achieved a partial response, 11 (34.4%) stable disease, and 16 (50%) progressive disease. The median duration of response was 9 months, the median TTP 7 months, and the overall median survival 6.5 months; the overall 1-year survival probability was 27.6%. Grade 3/4 neutropenia was observed in five (15.6%) patients and in two of them associated with fever. Grade 3 anemia and thrombocytopenia occurred in three (9%) and two (6.5%) patients, respectively. Non-hematologic toxicity was very mild with only one episode of grade 4 diarrhea and mucositis, respectively; two (6%) patients complained for grade 3 asthenia. CONCLUSION The combination of gemcitabine and docetaxel with prophylactic use of rhG-CSF is a safe and well-tolerated regimen for the treatment of patients with advanced NSCLC, who failed front-line treatment with cisplatin-based regimens.
Collapse
Affiliation(s)
- S Kakolyris
- Department of Medical Oncology, University General Hospital of Heraklion, Heraklion 71110, Crete, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mavroudis D, Agelaki S, Palamidas P, Kouroussis C, Harpidou A, Toubis M, Geroyianni A, Samonis G, Georgoulias V. The sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80699-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Agelaki S, Papadakis E, Tsiafaki X, Rapti A, Toubis M, Bania E, Kalbakis K, Kouroussis C, Androulakis N, Georgoulias V. A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81436-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Zervas J, Konstantopoulos K, Toubis M, Anagnostopoulos D, Cotsovoulou V. HLA typing in the Hong Kong Chest Service/British Medical Research Council Study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis 1989; 140:854. [PMID: 2782751 DOI: 10.1164/ajrccm/140.3.854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
10
|
Abstract
A significantly increased frequency of the HLA-B27 antigen was found in Greek adult patients suffering from pulmonary tuberculosis. This finding is discussed in connection with the literature, and it is suggested that the HLA system is involved in the pathogenesis of the disease.
Collapse
Affiliation(s)
- J Zervas
- First University Department of Medicine, Laiko General Hospital, Athens, Greece
| | | | | | | | | |
Collapse
|
11
|
Zervas J, Mavrikakis M, Kehayoglou K, Constantopoulos C, Toubis M. HLA antigens in diabetics with calcified shoulder periarthritis (CSP). Clin Exp Rheumatol 1986; 4:351-3. [PMID: 3791718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The distribution frequencies of HLA-A and B antigens was determined in 94 maturity onset diabetics (40 with CSP and 54 without CSP), as well as in 400 unrelated age- and sex-matched Greek controls. The standard NIH technique was used for tissue typing. There was an increased prevalence of the antigen B27 only in diabetics with CSP (35%) when compared either to the controls (6.8%) or to diabetics without CSP (9.2%). The calculated p-corrected values were Pc = 0.00027 and Pc greater than 0.005 respectively. These findings indicate that the MHC in man may control the genetic susceptibility of a subgroup of insulin-independent diabetics to develop CSP.
Collapse
|
12
|
Zervas J, Zoubopoulos H, Constantopoulos C, Theodorou SD, Toubis M, Fessas P. HLA antigens and congenital dislocation of the hip. Tissue Antigens 1983; 22:295-7. [PMID: 6648950 DOI: 10.1111/j.1399-0039.1983.tb01206.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The HLA-A and B phenotypes of 42 Greek children with CDH were determined and compared to those of 400 controls. A significant deviation of the frequency of the antigen HLA-A1, (Pc less than 0.003) was noted. It is suggested that immunogenetic factors are contributing to the development of the disease.
Collapse
|
13
|
Gregoriadis S, Zervas J, Varletzidis E, Toubis M, Pantazopoulos P, Fessas P. HLA antigens and otosclerosis. A possible new genetic factor. Arch Otolaryngol 1982; 108:769-71. [PMID: 6983341 DOI: 10.1001/archotol.1982.00790600013004] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The pattern of HLA antigens was studied in 68 Greek patients with otosclerosis with and without a family history of otosclerosis and in the members of seven families in which the disease occurs, and was compared with that of 400 unrelated control subjects. Fifty-six specific HLA antiserum samples were used to determine 27 HLA-A and B antigens with the two-stage standard National Institutes of Health assay. The results were modified as follows: There was a highly significant increase of the antigens HLA-A11, Bw35, and B14 only in the patients with family history. These findings, together with the observations from the family studies and the information of population epidemiology and HL distribution frequencies, indicate the possible role of HLA antigens in otosclerosis and corroborate the view that genetic factors are also involved.
Collapse
|